Eisai Inc.’s Perampanel Didn’t Significantly Reduce Epileptic Seizures in Study

Bloomberg -- Eisai Co.’s experimental epilepsy drug didn’t cut seizure rates significantly more than a placebo in patients who didn’t improve on previous treatments, a researcher said at the American Academy of Neurology meeting. While the study failed to find a definitive benefit for its two main goals, a third analysis favored by U.S. regulators showed patients had 26 percent to 35 percent fewer seizures over 28 days on perampanel, compared with 21 percent in those on a placebo, said Jacqueline French, director of the clinical trials consortium at New York University’s epilepsy center.